Patents by Inventor Andrew C. Webb
Andrew C. Webb has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11918837Abstract: There is provided a fit testing method comprising: providing a respirator donned by a wearer; providing a sensor in electrical communication with a sensing element, where the sensor is configured to monitor a particulate concentration parameter of a gas space within the respirator, and a second particulate concentration parameter of a gas space outside the respirator, where the sensor is attached to the respirator such that the respirator such that the weight of the sensor is supported by the respirator; and providing a reader configured to communicate with the sensor, where the reader is configured to provide a respirator fit parameter based on a comparison of the particulate concentration within the respirator to the particulate concentration parameter outside the respirator.Type: GrantFiled: August 31, 2018Date of Patent: March 5, 2024Assignee: 3M Innovative Properties CompanyInventors: Richard C. Webb, Andrew S. Viner, Daniel B. Taylor, Jessica L. T. Hauge, Jennifer L. Kamarainen, Jacob P. Vanderheyden, Silvia G. Guttmann, Kenneth B. L. Stanford
-
Patent number: 6506892Abstract: A novel immunoregulatory factor, designated IL-X, is described which has been isolated from Mycoplasma. The subject invention also concerns polynucleotides which encode IL-X. IL-X protein is a growth factor for EBV transformed human B lymphocytes and for murine helper T lymphocytes. Also taught are methods of raising antibodies to IL-X, and cloning of IL-X.Type: GrantFiled: October 29, 1998Date of Patent: January 14, 2003Inventors: Andrew C. Webb, Beverly A. Blazar
-
Publication number: 20010019713Abstract: A novel immunoregulatory factor, designated IL-X, is described which has been isolated from an Epstein-Barr virus (EBV) infected lymphoblastoid cell line. IL-X is a growth factor for EBV transformed human B lymphocytes and for murine helper T lymphocytes. Also taught are methods of raising antibodies to IL-X, and cloning of IL-X.Type: ApplicationFiled: January 16, 2001Publication date: September 6, 2001Inventors: Beverly A. Blazar, Andrew C. Webb
-
Patent number: 5998578Abstract: The subject invention concerns a nucleic acid comprising a nucleotide sequence encoding human interleukin-1 (IL-1), and fragments thereof, and the polypeptides and peptides obtained. Specifically, the subject invention comprises the cloning of a cDNA synthesized by reverse transcription of poly(A)RNA isolated from adherent human monocytes stimulated with bacterial endotoxin. Human IL-1 is useful to induce the production of IL-2 by activated T-cells; it also acts on B-cells and NK-cells. The subject invention further concerns antibodies that are immunoreactive with human IL-1.beta. proteins.Type: GrantFiled: June 7, 1995Date of Patent: December 7, 1999Assignees: New England Medical Center Hospitals, Inc., Massachusetts Institute of Technology, Trustees of Tufts College, Wellesley CollegeInventors: Philip E. Auron, Charles A. Dinarello, Andrew C. Webb, Alexander Rich, Sheldon M. Wolff, deceased
-
Patent number: 5985657Abstract: The subject invention concerns a nucleic acid comprising a nucleotide sequence encoding human interleukin-1 (IL-1), and fragments thereof, and the polypeptides and peptides obtained. Specifically, the subject invention comprises the cloning of a cDNA synthesized by reverse transcription of poly(A)RNA isolated from adherent human monocytes stimulated with bacterial endotoxin. Human IL-1 is useful to induce the production of IL-2 by activated T-cells; it also acts on B-cells and NK-cells.Type: GrantFiled: June 7, 1995Date of Patent: November 16, 1999Assignees: New England Medical Center Hospitals, Tufts College, Wellesley College, Massachusetts Institute of TechnologyInventors: Philip E. Auron, Charles A. Dinarello, Andrew C. Webb, Alexander Rich, Sheldon M. Wolff
-
Patent number: 5821053Abstract: A method for finding an agent which inhibits interaction between LIL-Stat protein and a nucleic acid having a LIL-Stat binding sequence is described. The LIL-Stat protein is contacted with the nucleic acid in the presence of an agent which inhibits or does not inhibit the interaction between the LIL-Stat protein and the nucleic acid. It is determined whether or not the agent inhibits this interaction. Also described are a method for treating an inflammatory response in a mammal, a therapeutic inhibitory agent suitable for treating or preventing an inflammatory response in a mammal, and DNA molecules having a DNA sequence encoding a binding site for the LIL-Stat protein.Type: GrantFiled: February 10, 1995Date of Patent: October 13, 1998Assignee: Center for Blood Research, Inc.Inventors: Philip E. Auron, Junichi Tsukada, Wayne R. Waterman, Andrew C. Webb
-
Patent number: 5681933Abstract: The subject invention concerns a nucleic acid comprising a nucleotide sequence encoding human interleukin-1 (IL-1), and fragments thereof, and the polypeptides and peptides obtained. Specifically, the subject invention comprises the cloning of a cDNA synthesized by reverse transcription of poly(A)RNA isolated from adherent human monocytes stimulated with bacterial endotoxin. The subject invention further concerns antibodies that are immunoreactive with human IL-1.beta. proteins. Human IL-1 is useful to induce the production of IL-2 by activated T-cells; it also acts on B-cells and NK-cells.Type: GrantFiled: June 1, 1993Date of Patent: October 28, 1997Assignees: New England Med. Center Hospitals, Tufts College, Wellesley College, Mass. Inst. of TechnologyInventors: Philip E. Auron, Charles A. Dinarello, Andrew C. Webb, Alexander Rich, Sheldon M. Wolff
-
Patent number: 5510462Abstract: The subject invention concerns a nucleic acid comprising a nucleotide sequence encoding human interleukin-1 (IL-1), and fragments thereof, and the polypeptides and peptides obtained. Specifically, the subject invention comprises the cloning of a cDNA synthesized by reverse transcription of poly(A)RNA isolated from adherent human monocytes-stimulated with bacterial endotoxin. Human IL-1 is useful to induce the production of IL-2 by activated T-cells; it also acts on B-cells and NK-cells.Type: GrantFiled: April 25, 1988Date of Patent: April 23, 1996Assignees: New England Medical Centers Hospitals, Inc., Trustees of Tufts College, Wellesley College, Massachusetts Institute of TechnologyInventors: Philip E. Auron, Charles A. Dinarello, Andrew C. Webb, Alexander Rich, Sheldon M. Wolff
-
Patent number: 5077219Abstract: The subject invention concerns truncated human Il-1 cDNA sequences which encode biologically-active novel human IL-1 proteins. These truncated human IL-1 cDNA sequences can be obtained by genetic engineering procedures using a clone of human IL-1 cDNA, having the accession number NRRL B-15770, as a starting material. The truncated human IL-1 cDNA sequences of the subject invention are contained in specified plasmids whose constructions are described in detail. Biologically-active human IL-1 proteins are useful to induce the production of IL-2 by activated T-cells. They also act on B-cells and NK-cells.Type: GrantFiled: August 21, 1990Date of Patent: December 31, 1991Assignees: New England Medical Center Hospitals, Wellesley College, Tufts College, MITInventors: Philip E. Auron, Andrew C. Webb, Lee Gehrke, Charles A. Dinarello, Lanny J. Rosenwasser, Alexander Rich, Sheldon M. Wolff
-
Patent number: 5001057Abstract: The subject invention concerns truncated human IL-1 cDNA sequences which encode biologically-active novel human IL-1 proteins. These truncated human IL-1 cDNA sequences can be obtained by genetic engineering procedures using a clone of human IL-1 cDNA, having the accession number NRRL B-15770, as a starting material. The truncated human IL-1 cDNA sequences of the subject invention are contained in specified plasmids whose constructions are described in detail. Biologically-active human IL-1 proteins are useful to induce the production of IL-2 by activated T-cells. They also act on B-cells and NK-cells.Type: GrantFiled: April 21, 1988Date of Patent: March 19, 1991Assignees: New England Medical Center, Tufts College, Wellesley College, MITInventors: Philip E. Auron, Andrew C. Webb, Lee Gehrke, Charles A. Dinarello, Lanny J. Rosenwasser, Alexander Rich, Sheldon M. Wolff
-
Patent number: 4923807Abstract: The invention is directed to an Arg-Serpin human plasminogen activator inhibitor designated PAI-2. This protein is prepared via recombinant DNA means. The invention also includes other serpins which can be made by amino acid substitutions or deletions in conserved regions of PAI-1 and PAI-2, as shown in FIG. 4. The proteins of the invention can be used to inhibit, or at least modulate, human plasminogen activator activity in a variety of physiological conditions, e.g., fibrinolysis, tumor metastasis, and tumor growth.Type: GrantFiled: February 6, 1987Date of Patent: May 8, 1990Assignees: New England Medical Center Hospitals Inc., Tufts College, Wellesley College, MITInventors: Andrew C. Webb, Philip E. Auron
-
Patent number: 4766069Abstract: The subject invention concerns a nucleic acid comprising a nucleotide sequence encoding human interleukin-1 (IL-1), and fragments thereof, and the polypeptides and peptides obtained. Specifically, the subject invention comprises the cloning of a cDNA synthesized by reverse transcription of poly(A)RNA isolated from adherent human monocytes stimulated with bacterial endotoxin. Human IL-1 is useful to induce the production of IL-2 by activated T-cells; it also acts on B-cells and NK-cells.Type: GrantFiled: January 8, 1987Date of Patent: August 23, 1988Assignees: New England Medical Center, Tufts College, Wellesley College, MITInventors: Philip E. Auron, Charles A. Dinarello, Andrew C. Webb, Alexander Rich, Sheldon M. Wolff
-
Patent number: 4762914Abstract: The subject invention concerns truncated human IL-1 cDNA sequences which encode biologically-active novel human IL-1 proteins. These truncated human IL-1 cDNA sequences can be obtained by genetic engineering procedures using a clone of human IL-1 cDNA, having the accession number NRRL B-15770, as a starting material. The truncated human IL-1 cDNA sequences of the subject invention are contained in specified plasmids whose constructions are described in detail. Biologically-active human IL-1 proteins are useful to induce the production of IL-2 by activated T-cells. They also act on B-cells and NK-cells.Type: GrantFiled: February 11, 1985Date of Patent: August 9, 1988Inventors: Philip E. Auron, Andrew C. Webb, Lee Gehrke, Charles A. Dinarello, Lanny J. Rosenwasser, Alexander Rich, Sheldon M. Wolff